

Q1 2021 Investor Presentation

Forward-Looking Statements

This presentation contains forward-looking statements. All statements other than statements of historical facts may be forward-looking statements. Forward-looking statements generally relate to future events and include, without limitation, projections, forecasts and estimates about possible or assumed future results of our business, financial condition, liquidity, results of operations, plans, and objectives. Some of these statements may include words such as "expects," "anticipates," "believes," "estimates," "targets," "plans," "potential," "intends," "projects," and "indicates."

Although they reflect our current, good faith expectations, these forward-looking statements are not a guarantee of future performance, and involve a number of risks, uncertainties, estimates, and assumptions, which are difficult to predict. Some of the factors that may cause actual outcomes and results to differ materially from those expressed in, or implied by, the forward-looking statements include, but are not necessarily limited to: the ongoing assessment of the cyber incident, material legal, financial and reputational risks resulting from such incident and the related operational disruptions, the duration and magnitude of the COVID-19 pandemic and related containment measures; our ability to manage our growth; the execution of our business strategies, implementation of new initiatives, and improved efficiency; our sales and marketing efforts; our manufacturing capacity, performance, and cost; our ability to obtain future regulatory approvals; our financial estimates and needs for additional financing; consumer acceptance of and competition for our clear aligners; our relationships with retail partners and insurance carriers; our R&D, commercialization, and other activities and expenditures; the methodologies, models, assumptions, and estimates we use to prepare our financial statements, make business decisions, and manage risks; laws and regulations governing remote healthcare and the practice of dentistry; our relationships with vendors; the security of our operating systems and infrastructure; our risk management framework; our cash and capital needs; our intellectual property position; our exposure to claims and legal proceedings; and other factors described in our filings with the Securities and Exchange Commission, including but not limited to our Annual Report on Form 10-K for the year ended December 31, 2020 and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2021.

New risks and uncertainties arise over time, and it is not possible for us to predict all such factors or how they may affect us. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. We are under no duty to update any of these forward-looking statements after the date of this presentation to conform these statements to actual results or revised expectations. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this presentation.


Market and Industry Data

This presentation also contains estimates and other statistical data obtained from independent parties and by us relating to market size and growth and other data about our industry and ultimate consumers. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates and data. In addition, projections, assumptions, and estimates of our future performance and the future performance of the geographic and other markets in which we operate are necessarily subject to a high degree of uncertainty and risk.

Non-GAAP Financial Measures

This presentation contains certain non-GAAP financial measures, including adjusted EBITDA ("Adjusted EBITDA"). These non-GAAP measures should not be considered in isolation or as a substitute for the related GAAP measures, and other companies may define such measures differently. We provide a reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures in the appendix to this presentation and in our Current Report on Form 8-K announcing our quarterly earnings results, which can be found on the SEC's website at www.sec.gov and our website at investors.smiledirectclub.com.

This presentation is a supplement to, and should be read in conjunction with, SmileDirectClub's earnings release for the quarter and March 31, 2021.




WHATWE STAND FOR

Our mission is to democratize access to a smile each and every person loves by making it affordable and convenient for everyone.



Why Our Club Members Choose SDC.

Orthodontists have traditionally purchased invisible aligners from a wholesaler or manufacturer, marked up the cost by 3x, and then sold them to consumers for \$5,000-\$8,000. Our proprietary telehealth platform offers consumers the ability to get the same clinically safe and effective treatment, but without the 3x markup.



We provide a global telehealth platform with unique value propositions. smile OIRECT CLU **Mission-driven brand with positive** 1 member experience. **Omni-channel presence with** SmileShops, impression kits, and GP Access **Control of our destiny** footprint. Convenience **Compelling unit economics** Exclusive licensed doctor network across 13 **Affordability** Accelerating growth 3 countries¹, powered by our Telehealth platform **Members Business** SmileCheck. SmilePay captive financing increases accessibility and reduces purchasing friction. Vertical integration allows us to optimize every step of the member journey and continuously improve the process.

Visionary, founder-led company with a history of disrupting incumbents.

6


Club Member Satisfaction






SDC has built a brand at scale that our members love.

We have made considerable progress on brand perception, and our member satisfaction scores consistently tracked higher than DTC peers



Google Reviews & Member Sentiment





smile Source: Internal company surveys, public information. Data as of Apr. 2021.

OIRECT CLUP

Note: DTC rating is an average of DTC competitors. DSO rating is average of two larger DSOs in the US.

(1) Reflects most recent prior brand survey response.. (2) Google rating. (3) All time average rating. (4) Company website.

Q1 Financial Results.





Q1 2021 results.

- Revenue for the quarter was \$199.5 million, which represents a sequential increase of 8% over Q4 2020
 - Above the high end of our long-term target range
 - Also represents a record quarter for revenue in the history of SDC
- Gross margin for the quarter was 76%, up 225 basis points from Q4 2020, and a 640-basis point improvement versus Q1 2020
- Net loss for the quarter was (\$95.6mm), which includes a \$47.6mm loss on extinguishment of debt
- Q1 Adjusted EBITDA⁽¹⁾ was \$4.9mm for the quarter, down \$2m from Q4 due to higher selling and marketing expenses, mostly associated with international ramp
 - US/Canada Adjusted EBTIDA was \$11.6mm, implying a 7% Adjusted EBITDA margin
 - Rest of World Adjusted EBITDA was (\$6.7mm)
- Our long-term financial targets remain intact:


smile

PECTON

- Average revenue growth of 20-30% per year for the next 5 years.
- Adjusted EBITDA⁽¹⁾ margins of 25-30% as we scale during that time period.
 - This is driven by an 85% gross margin, 40-45% sales and marketing margin, and a 15% G&A margin.

	Ç	21 2021	QoQ
Net Revenue	\$	199.5mm	8%
Gross Profit	\$	151.5mm	11%
Gross Margin %		76%	225bps
Adjusted EBITDA ⁽¹⁾	\$	4.9mm	(31%)
EPS, Diluted	\$	(0.25)	NM

Revenue (\$ in millions)



(1) Adjusted EBITDA is a non-GAAP financial measure. See appendix for definition of Adjusted EBITDA.

Gross margin.

- Gross margin for the quarter was 76%, a 225bps increase sequentially and a 640-basis point improvement versus Q1 2020. Gross profit was up 11% sequentially.
 - This was supported by the increase in aligners produced using our second-generation automated manufacturing
 - We expect gross margin to continue to strengthen as volumes grow
- On COGS, we are making good progress on manufacturing automation with our 2nd Gen machines now producing approximately 70% of our aligners.
 - We plan to increase that percentage significantly over the course of the year, and we expect approximately 90% by the end of Q2.
- As we have often stated, we believe streamlining our cost profile through operational efficiencies, will not only improve our margin profile, but more importantly, will provide a consistently superior customer experience that meets our expectations and upholds our brand promise.
- Our long-term gross margin target of 85% of revenue remains intact.





Marketing & selling.

- Marketing and selling expenses came in at \$97 million or 48.7% of net revenue in the quarter.
 - This is compared to 72% of net revenue in Q1 of 2020
- Our efficient deployment of acquisition spend, continued advancements in aided awareness and referral rates, and access to highly efficient lead sources, have positioned us well to continue to perform well against our long-term targets.
 - With 75% of the total market opportunity overseas, we also continue to invest heavily in brand building internationally. This is driving our near-term sales and marketing as a percent of revenue higher than our long-term targets as we scale our brand in these markets
- On SmileShops, we had 126 permanent locations as of quarter end, and held 156 pop-up events over the course of the quarter, for a total of 282 location sites.
 - These pop-up events are a critical component to supporting our demand, function in the same capacity as a permanent SmileShop, and enable us to fulfill demand that is coming through aided awareness, referrals, and marketing.
- Long-term target of 40-45% margin remains intact.

Quarter	Q1	Q2	Q3	Q4	Q1
	2020	2020	2020	2020	2021
Referrals as a % of Aligner Orders	20%	21%	23%	22%	21%

Marketing & selling expenses (\$ in millions)






General & administrative.

- General and administrative expenses were \$81 million in Q1, compared to \$78 million in Q4 2020.
 - G&A expenses were up \$3 million sequentially due to higher one-time stockbased compensation
 - Adjusting for this, G&A expenses were down \$6 million on a quarter over quarter basis.
 - Excluding D&A, stock-based compensation, and one-time items, G&A expenses remain down \$11 million, or 15%, versus Q1 of 2020.
- The stability throughout the quarter was a direct result of the cost control initiatives we discussed on prior earnings calls.
 - We plan to stay vigilant with cost control throughout the remainder of the year and beyond, as we focus on continuing to leverage this line item
- Our long-term target of 15% of revenue remains intact.

smile




Other expenses, Adjusted EBITDA & net income.

- Interest Expense:
 - Interest expense was \$17.6 million in the first guarter, primarily associated with borrowings on indebtedness from our prior credit facility. This expense will decline significantly now that we have refinanced with our new convert.
- Loss on extinguishment of debt:
 - We had a \$47.6mm loss on extinguishment of debt relating to the repayment of the prior credit facility. This expense includes the make whole amount paid in connection with the termination of the agreement, the remaining unamortized costs and unaccreted value of warrants.
- Store Closure Costs
 - We had expense of \$1.1mm associated with optimizing our store footprint.
- Other:


smile OIRECT CLU

- Expense of \$0.9mm primarily reflects unrealized foreign exchange loss
- Q1 Adjusted EBITDA⁽¹⁾ was \$4.9mm for the guarter
 - US/Canada Adjusted EBTIDA was \$11.6mm, implying a 7% margin
 - Rest of World Adjusted EBITDA was (\$6.7mm)



Net income (Loss) (\$ in millions)

Adj. EBITDA⁽¹⁾ (\$ in millions)



(1) Adjusted EBITDA is a non-GAAP financial measure. See appendix for definition of Adjusted EBITDA.

Balance sheet highlights.

- We ended Q1 with \$434.5 million in cash and cash equivalents.
- Cash from operations for the first quarter was (\$28.3) million.
- Cash spent on investing for the first quarter was \$23.0 million, mainly associated with capitalized labor, capitalized software, and building our manufacturing automation.
- Free cash flow⁽¹⁾ was slightly lower versus Q4 2020, associated with timing of accounts payable payments, and growth in accounts receivable

 $(1)\ {\rm Free}\ {\rm Cash}\ {\rm Flow}\ {\rm is}\ {\rm a}\ {\rm non-GAAP}\ {\rm financial}\ {\rm measure}.$ See appendix for definition of Free Cash Flow.



(\$ in millions)	Q1 2020	Q2 2020	Q3 2020	Q4 2020	Q1 2021
Cash	\$224.4	\$389.0	\$373.0	\$316.7	\$434.5
Debt	\$221.4	\$420.3	\$415.7	\$408.6	\$745.7
Accounts Receivable, Net	\$345.3	\$311.8	\$302.0	\$293.3	\$300.0
Cash Flow from Operations	\$(70.4)	\$(15.5)	\$17.2	(\$14.9)	(\$28.3)
Cash Flow from Investing	(\$28.1)	(\$19.7)	(\$20.9)	(\$28.4)	(\$23.0)
Free Cash Flow	(\$98.5)	(\$35.2)	(\$3.7)	(\$43.3)	(\$51.3)

- On SmilePay, which drives our accounts receivable, in Q1 2021, SmilePay as a percentage of total aligners purchased was 61%, just above Q4 2020 (60%) and below FY 2020 (64%).
- Overall, SmilePay has continued to perform well, and our delinquency rates in Q1 were consistent with prior quarters. Because we keep a credit card on file, and have a low monthly payment, we expect SmilePay to continue to perform well.

Convertible Debt Offering.

- Deal launched at a size of \$350 million and was later upsized to \$650 million due to strong institutional demand.
 - In addition, the bookrunners exercised their full greenshoe option to purchase \$97.5 million convertible notes, bringing the full offering size to \$747.5 million.
 - Notes were priced with a 0% coupon, and a 40% conversion premium.
 - Notes mature February 2026
 - In conjunction, SDC entered into a capped call that will fully offset any potential equity dilution from conversion of the notes.
- This convertible debt financing strengthens our balance sheet, with minimal equity dilution, and fortifies us against a protracted COVID environment, while also enabling to us to comfortably execute our growth strategy over the coming years, while also investing in R&D, innovation, and other business development opportunities.

Convertible Debt Key Terms					
Base Deal Size	\$650 million				
Green Shoe (exercised)	\$97.5 million				
Coupon	0.00%				
Conversion Premium/Price	40.0% / \$18.06				
Settlement Date	February 9, 2021				
Maturity	February 1, 2026				

Capped Call Key Terms					
Capped Call Lower Strike	40.0% / \$18.06				
Capped Call Upper Strike	100.0% / \$25.80				
Net Premium	9.3% of proceeds				
Effective all-in Rate/Terms	~2.0% Cost of Capital up 100%				



Q2 2021 & Long-Term Outlook





Cybersecurity Incident

- As disclosed in an 8K filed on May 3, 2021, the Company experienced a systems outage caused by a cybersecurity incident on April 14, 2021
- We immediately mobilized our internal engineering security team and promptly implemented a series of containment and remediation measures to address the attack including temporarily isolating and shutting down affected systems and related manufacturing operations
- We have also engaged a leading forensic information technology firm to assist with our investigation into the incident.
- At this time, the Company is not aware of any data loss from, or other loss of assets as a result of, the Incident, including any exposure of customer or team member information.
- As a result of these efforts, we were able to successfully block the attack, no ransom was paid, and SDC's systems and operations are back online and performing normally.




Q2 guidance & long-term outlook.

- Our Long-Term plan remains intact. We are managing the business to drive towards our long-term financial targets, which include 20-30% revenue growth per year
- Without the cyber-attack, we expected revenue to be up 5-7% sequentially, and we also expected Adjusted EBITDA to come in slightly ahead of Q1 levels, as we continue to invest marketing dollars to build brand equity outside of the US and Canada.
- In light of the cyber-attack, and the associated business disruption, we are adjusting our revenue expectations for Q2 based on our best estimates of the possible impact. While it is still early to have complete certainty as to how the impacted leads will ultimately convert, as of today we expect for Q2:
 - Revenue to be approximately \$195 \$200mm
 - Adjusted EBITDA⁽¹⁾ to be approximately breakeven, as we recover from the cyber-attack, and continue to lean into marketing spend in international markets
 - As a reminder, marketing dollars we spend today, have a long tail.
- Our long-term objectives have not changed:
 - We remain laser focused on providing the best club member experience, and our mantra remains to drive controlled and profitable growth.
 - We remain the low-cost provider, with brand presence, no pricing pressure, and no real competitor that provides an end to end vertically integrated platform for the consumer.
 - We will continue to make strategic investments in the professional channel, international growth, and in penetrating new demographics to drive controlled growth, all wrapped around continued spend on innovation and R&D.
 - We continue to see favorable industry dynamics with broader acceptance of telehealth and specifically tele-dentistry, minimal penetration against our total addressable market, and clear aligners gaining share in the overall industry.
 - All of these position us well for long-term success.



Growth Initiatives.


Continued momentum across our three key revenue growth drivers.



Cost Levers.

PECT CLU

Leveraging automation, sales and marketing efficiency, and cost discipline to drive towards profitability.



(1) Adjusted EBITDA is a non-GAAP financial measure. See appendix for definition of Adjusted EBITDA.

Appendix.





Net Income to adjusted EBITDA.

	Three Months Ended March 31,				
(In thousands)	2021	2020			
Net loss	\$(95,645)	\$(107,400)			
Depreciation and amortization	16,460	11,442			
Total interest expense	17,566	4,022			
Income tax expense	1,707	1,974			
Other store closure and restructuring costs	1,128				
Loss on extinguishment of debt	47,631	_			
Equity-based compensation	15,159	16,396			
Other non-operating general and administrative costs ⁽¹⁾	912	6,584			
Adjusted EBITDA	\$4,918	\$(66,982)			

smile \mathcal{P}_{kerrev} Note: Adjusted EBITDA is a non-GAAP financial measure.

(1) Includes a one-time legal expense settlement of \$5.0mm, offset by currency gains recognized in the quarter of \$3.1mm.

Cash Flow From Operations to Free Cash Flow.

	Three Months Ended March 31,				
(In thousands)	2021	2020			
Cash Flow From Operations	\$(28,338)	\$(70,395)			
Cash Flow From Investing	(22,981)	(28,123)			
Free Cash Flow	\$(51,319)	\$(98,518)			

Gross to net revenue bridge.

(\$ in millions; except for Aligners Shipped and ASP)

	Q	1 2020	Q	2 2020	С	3 2020	Q	4 2020	Q	l 2021
Total Unique Aligner Orders Shipped(1)	1	22,751		57,136		93,301		101,794	10)6,345
Average Aligner Gross Sales Price ("ASP")		\$1,770		\$1,817		\$1,794		\$1,820	ç	51,860
Aligner Gross Revenue	\$	217.3	\$	103.8	\$	167.4	\$	185.3	\$	197.8
Implicit Price Concession(2)		(21.3)		(9.3)		(13.4)		(14.2)		(12.8)
Reserves and other adjustments(3)		(25.1)		(16.6)		(14.7)		(16.1)		(17.5)
Aligner Revenue(4)	\$	170.9	\$	77.9	\$	139.3	\$	155.0	\$	167.5
Financing Revenue(5)		12.7		12.7		12.0		12.0		10.7
Other Revenue and adjustments(6)		13.0		16.5		17.2		17.6		21.3
Total Net Revenue	\$	196.7	\$	107.1	\$	168.5	\$	184.6	\$	199.5

Note: All information in this file is publicly available from our SEC filings.

(1) Each unique aligner order shipped represents a single contracted member.

(2) Estimated based on historical write-off percentages and expected net collections. Excludes implicit price concessions associated with financing 'revenue starting in 2020 \$2.035mm for Q120, \$1.997 for Q220, \$1.927 for Q320,

\$1.914 for Q420, and \$1.748 for Q121. See footnote 5 below.

(3) Includes impression kit revenue, refunds and sales tax.

(4) As defined in quarterly and annual filings (Aligner Gross Revenue less IPC and Reserves and other adjustments).

- (5) Represents interest income earned on our SmilePay financing program, net of IPC starting in 2019, as noted in footnote 2 above.
- (6) Includes net revenue related to retainers, whitening, and other ancillary products.

Journal of Dental Research and Reports: Clinical study confirms effectiveness of clear aligner teleorthodontic care

"The aim of the study was threefold:

- to objectively assess the clinical effectiveness of teleorthodontic treatment with clear aligners on maxillary and mandibular incisor alignment utilizing the SmileDirectClub® teleorthodontic platform.
- to objectively measure differences in clinical effectiveness between treatment supervised by general practitioners versus orthodontic specialists
- to subjectively consider patient satisfaction after the teleorthodontic treatment with clear aligners and the relationship between satisfaction and whom the treatment was provided by."

Conclusion:

"Study data suggest that teleorthodontic treatment with clear aligners is clinically effective in the correction of maxillary and mandibular incisor alignment problems (crowding or spacing) less than 6 mm. There appears to be no difference in clinical effectiveness between teleorthodontic treatment with clear aligners supervised by general practitioners versus orthodontic specialists. Patient satisfaction after teleorthodontic treatment with clear aligners seems to be unrelated to who provided the treatment, general practitioner or orthodontic specialist."

- Dr. Marc B. Ackerman, Journal of Dental Research and Reports, "Teleorthodontic treatment with clear aligners: An analysis of outcome in treatment supervised by general practitioners versus orthodontic specialists," Volume 2:1-4, May 16, 2019



